Non-hormonal treatment strategies for vasomotor symptoms: A critical review

Drugs

Volumn 71, Issue 3, 2011, Pages 287-304

  Hall, Elise ^a   Frey, Benicio N ^a   Soares, Claudio N ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Acupuncture; Cimicifuga; Citalopram; Clonidine; Desvenlafaxine; Duloxetine; Escitalopram; Estradiol congeners; Eszopiclone; Exercise; Fluoxetine; Fluvoxamine; Gabapentin; Hot flashes; Hypericum; Menopause; Mirtazapine; Omega 3 fatty acids; Paroxetine; Quetiapine; Research and development; Sertraline; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIESTROGEN; ATYPICAL ANTIPSYCHOTIC AGENT; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; ISOFLAVONE DERIVATIVE; LEUPRORELIN; NORETHISTERONE; PAROXETINE; PLACEBO; PROGESTERONE; PSYCHOTROPIC AGENT; QUETIAPINE; RALOXIFENE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; UNINDEXED DRUG; VENLAFAXINE;

ACUPUNCTURE; ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ANXIETY DISORDER; CIMICIFUGA RACEMOSA; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERICUM PERFORATUM; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; MENOPAUSE; MONOTHERAPY; MOOD DISORDER; NIGHT SWEAT; OUTCOME ASSESSMENT; OVARIECTOMY; PAIN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICIAN; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED CLOVER; REMISSION; RISK REDUCTION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SURGICAL TECHNIQUE; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASODILATATION; VASOMOTOR DISORDER; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; FEMALE; HOT FLASHES; HUMANS; HYPERHIDROSIS; NEUROTRANSMITTER UPTAKE INHIBITORS; POSTMENOPAUSE; SEROTONIN UPTAKE INHIBITORS; SYMPATHOMIMETICS; VASOMOTOR SYSTEM;

CIMICIFUGA; HYPERICUM;

EID: 79951648200     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585360-000000000-00000     Document Type: Conference Paper

References (106)

1. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985; 8: 261-8.
2. Nelson HD. Menopause. Lancet 2008; 371 (9614): 760-70. (Pubitemid 351288876)
3. Gundlah C, Pecins-Thompson M, Schutzer WE, et al. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol 1999; 63 (2): 325-39. (Pubitemid 29036984)
4. Gundlah C, Lu NZ, Mirkes SJ, et al. Estrogen receptor beta (ERbeta) mRNA and protein in serotonin neurons of macaques. Brain Res Mol Brain Res 2001; 91 (1-2): 14-22. (Pubitemid 32701999)
5. Lu H, Ozawa H, Nishi M, et al. Serotonergic neurones in the dorsal raphe nucleus that project into the medial preoptic area contain oestrogen receptor beta. J Neuroendocrinol 2001 Oct; 13 (10): 839-45. (Pubitemid 32910504)
6. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181 (1): 66-70. (Pubitemid 29343332)
7. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001; 13: 453-64. (Pubitemid 32590928)
8. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007; 10 (6): 247-57.
9. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002; 77 (3): 487-90. (Pubitemid 34177202)
10. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebocontrolled trial. Arch Gen Psychiatry 2001; 58 (6): 529-34. (Pubitemid 32523731)
11. Lobo RA, Bé lisle S, Creasman WT, et al. Should symptomatic menopausal women be offered hormone therapy? Med Gen Med 2006; 8 (3): 40.
12. Maki PM, Sundermann E. Hormone therapy and cognitive function. Hum Reprod Update 2009; 15 (6): 667-81.
13. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15 (4 Pt 1): 584-602.
14. Schonberg MA, Davis RB, Wee CC. After the Women's Health Initiative: decision making and trust of women taking hormone therapy. Womens Health Issues 2005; 15 (4): 187-95. (Pubitemid 41033056)
15. McIntyre RS, Konarski JZ, Grigoriadis S, et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005; 172 (1): 57-9. (Pubitemid 40138253)
16. Brett KM, Keenan NL. Complementary and alternative medicine use among midlife women for reasons including menopause in the United States: 2002. Menopause 2007; 14 (2): 300-7. (Pubitemid 46673482)
17. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005; 23 (2): 117-25. (Pubitemid 40604897)
18. Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis 2004; 46 (4): 349-73. (Pubitemid 38201296)
19. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 1994; 62 (3): 283-324. (Pubitemid 24248421)
20. Azmitia EC, Gannon PJ. The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. Adv Neurol 1986; 43: 407-68.
21. Aston-Jones G, Shipley MT, Chouvet G, et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991; 88: 47-75.
22. Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008 Feb; 121 (2): 159-62.e1.
23. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289: 2827-34. (Pubitemid 37430118)
24. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005 Oct; 23 (28): 6919-30.
25. Gordon PR, Kerwin JP, Boesen KG, et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006; 13 (4): 568-75. (Pubitemid 44079527)
26. Grady D, Cohen B, Tice J, et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007 Apr; 109 (4): 823-30. (Pubitemid 46559068)
27. Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther 2007 Mar/ Apr; 24 (2): 448-61. (Pubitemid 46988389)
28. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12 (1): 18-26. (Pubitemid 40204889)
29. Kalay AE, Demir B, Haberal A, et al. Efficacy of citalopram on climacteric symptoms. Menopause 2007; 14 (2): 223-9. (Pubitemid 46673473)
30. Kupperman HS, Blatt MHG, Wiesbaden H, et al. Comparative clinical evaluation of estrogen preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953; 13: 688-703.
31. Kupperman HS, Wetchler BB, Blatt MHG. Contemporary therapy of the menopausal syndrome. J Am Med Assoc 1959; 171: 1627-37.
32. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996 Jul; 24 (3): 161-75.
33. Evans MI, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161-6. (Pubitemid 40189927)
34. Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111 (1): 77-87.
35. Archer DF, Seidman L, Constantine GD, et al. A doubleblind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200: e1-10.
36. Davies A, Hendrich J, Van Minh AT, et al. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007; 28 (5): 220-8. (Pubitemid 46661004)
37. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22 (1): 27-47. (Pubitemid 350243365)
38. Toulis KA, Tzellos T, Kouvelas D, et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther 2009; 31 (2): 221-35.
39. Guttoso Jr T, Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101 (2): 337-45. (Pubitemid 36170136)
40. Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008; 15 (2): 310-8. (Pubitemid 351354993)
41. Reddy SY, Warner H, Guttoso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006 Jul; 108 (1): 41-8. (Pubitemid 44336843)
42. Oldenhave A, Lazlo JB, Jaszmann MD, et al. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993; 168: 772-80. (Pubitemid 23095992)
43. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression: results from theMassachusetts Women's Health Study. Ann Epidemiol 1994; 4: 214-20. (Pubitemid 24154300)
44. Collins A, Landgren BM. Reproductive health, use of estrogen and experience symptoms in perimenopausal women: a population based study. Maturitas 1995; 20: 100-11.
45. Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause Int 2008; 14: 123-8.
46. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007; 103: 267-72. (Pubitemid 47445776)
47. Woods NF, Smith-DiJulio K, Percival DB, et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause 2008; 15: 223-32. (Pubitemid 351354981)
48. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006; 63 (4): 385-90.
49. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63 (4): 375-82.
50. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003 Apr; 64 (4): 473-9. (Pubitemid 36547294)
51. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, NY Psychiatric Institute, 1996.
52. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 1: 25-31. (Pubitemid 28247565)
53. Montgomery SA, A ? sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9. (Pubitemid 9136500)
54. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006; 13 (5): 780-6. (Pubitemid 44435032)
55. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010; 17 (4): 700-11.
56. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
57. Hauser GA, Huber IC, Keller PJ, et al. Evaluation der klimakterischen Beschwerden (Menopause Rating Scale (MRS)). Zentralbl Gynakol 1994; 116: 16-23. (Pubitemid 24040851)
58. Schenider HPG, Heinemann LAJ, Rosemeier HP, et al. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 1999; 2: 59-64.
59. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotonin- norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007 Jun; 68 (6): 943-50. (Pubitemid 47015497)
60. Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oopherectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res 2005 Apr; 31 (2): 107-14. (Pubitemid 40563032)
61. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70.
62. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12 (2): 114-22.
63. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002 Mar; 20 (6): 1578-83. (Pubitemid 34260538)
64. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000 Dec; 356: 2059-63. (Pubitemid 32009821)
65. Barton D, La Vasseur B, Loprinzi C, et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002; 29 (1): 33-40.
66. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007; 12: 124-35. (Pubitemid 46150798)
67. Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients: a double-blind, randomized trial. Ann Oncol 2007 Jan; 18: 689-93. (Pubitemid 46523272)
68. Soares CN, Frey BN, Haber E, et al. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause- related symptoms. J Clin Psychopharm 2010 Oct; 30 (5): 612-5.
69. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001; 22: 979-89. (Pubitemid 33152683)
70. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res 2008; 58: 8-14.
71. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a doubleblind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003; 44: 67-77.
72. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005; 105: 1074-83. (Pubitemid 40571028)
73. Frei-Kleiner S, Schaffner W, Rahlfs VW, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005; 51: 397-404. (Pubitemid 41019367)
74. Newton KM, Reed SD, Grothaus L, et al. The Herbal Alternatives for Menopause (HALT) study: background and study design. Maturitas 2005; 52: 134-46. (Pubitemid 41368036)
75. Newton Km, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145: 869-79. (Pubitemid 351639962)
76. BaiW,Henneicke-Von ZepelinHH,Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58: 31-41. (Pubitemid 47268705)
77. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992; 14: 211-4.
78. Shams T, Setia MS, Hemmings R, et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med 2010; 16 (1): 36-44.
79. Geller SE, Shulman LP, Van Breeman RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009; 16 (6): 1156-66.
80. Atkinson C, Warren RML, Sala E, et al. Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial. Breast Cancer Res 2004; 6 (3): 170-9.
81. Jeri AR. The use of an isoflavone supplement to relieve hot flashes. Female Patient 2002; 27: 35-7.
82. Van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42: 187-93. (Pubitemid 34876810)
83. Baber RJ, Templeman C, Morton T, et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999; 2: 85-92. (Pubitemid 29333647)
84. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2: 79-84. (Pubitemid 29333646)
85. Tice JA, Ettinger B, Ensrund K, et al. Phytoestrogen supplements for the treatment of hot flashes. The Isoflavone Clover Extract (ICE) study: a randomized controlled trial. JAMA 2003; 290: 207-14.
86. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006 May; 295 (17): 2057-71. (Pubitemid 44794007)
87. Jacobs A, Wegewitz U, Sommerfeld C, et al. Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review. Mol Nutr Food Res 2009; 53: 1084-97.
88. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas 2010; 66: 333-43.
89. Abdali K, Khajehei M, Tabatabaee HR. Effect of St. John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebocontrolled study. Menopause 2010; 17 (2): 326-31.
90. Borud EK, Alraek T, White A, et al. The Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, a randomized control trial. Menopause 2009; 16 (3): 484-93.
91. Borud EK, Alraek T, White A, et al. The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause 2010; 17 (2): 262-8.
92. Kim KH, Kang KW, Kim DI, et al. Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women: a multicentre randomized clinical trial. Menopause 2010; 17 (2): 269-80.
93. Huang MI, Nir Y, Chen B, et al. A randomized controlled pilot study of acupuncture for postmenopausal hot flashes: effect on nocturnal hot flashes and sleep quality. Fertil Steril 2006 Sep; 86 (3): 700-10. (Pubitemid 44307030)
94. Buysse DJ, Reynolds 3rd CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989 May; 28 (2): 193-213. (Pubitemid 19144991)
95. Thurston RC, Joffe H, Soares CN, et al. Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. Menopause 2006; 13 (4): 553-60. (Pubitemid 44079525)
96. Daley AJ, Stokes-Lampard HJ, MacArthur C. Exercise to reduce vasomotor and other menopausal symptoms: a review. Maturitas 2009; 63: 176-80.
97. Freeman MP, Hibbeln JR, Silver M, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause. Epub 2010 Oct 27.
98. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006 Dec; 108 (6): 1402-10. (Pubitemid 44901014)
99. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010 Feb; 171: e1-11.
100. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297-307. (Pubitemid 32677404)
101. Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 2010; 67 (4): 296-308.
102. Biglia N, Kubatzki F, Sgandurra P, et al. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J 2007; 13 (5): 490-5. (Pubitemid 47329337)
103. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818-24. (Pubitemid 41557381)
104. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12: 155-8. (Pubitemid 24020635)
105. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Centre Community Clinical Oncology Program Study. Ann Intern Med 2000; 132: 788-93. (Pubitemid 30317793)
106. Al-Akoum M, Maunsell E, Verreault R, et al. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009; 16 (2): 307-14